

Twist Bioscience to Present at the 2022 UBS Global Healthcare Conference

May 18, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 18, 2022-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on Monday, May 23 at 9:15 a.m. Eastern Time in New York.

The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live event.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005400/en/

For Twist Bioscience Angela Bitting SVP, Corporate Affairs 925- 202-6211 media@twistbioscience.com

Source: Twist Bioscience Corporation